HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs

  • HAYA Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), closed its CHF 18 million Seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq, and Viva BioInnovator. HAYA Therapeutics was a Venture Kick winner and a Venture Leader Life Sciences in 2018 and one of the TOP 100 Swiss Startups in 2020. We interviewed Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics, about the use of these funds and his entrepreneurial path